PMC:7228307 / 474-708 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"21","span":{"begin":109,"end":113},"obj":"Gene"},{"id":"26","span":{"begin":206,"end":212},"obj":"Disease"}],"attributes":[{"id":"A21","pred":"tao:has_database_id","subj":"21","obj":"Gene:2213"},{"id":"A26","pred":"tao:has_database_id","subj":"26","obj":"MESH:D009369"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"monoclonal antibodies (mAbs) are approved or in late stage clinical trials, many of which harness the potent FcγR‐mediated effector systems to varying degrees. This is most evident for antibodies targeting cancer cells inducing antibo"}

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T5","span":{"begin":213,"end":218},"obj":"Body_part"}],"attributes":[{"id":"A5","pred":"fma_id","subj":"T5","obj":"http://purl.org/sig/ont/fma/fma68646"}],"text":"monoclonal antibodies (mAbs) are approved or in late stage clinical trials, many of which harness the potent FcγR‐mediated effector systems to varying degrees. This is most evident for antibodies targeting cancer cells inducing antibo"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T2","span":{"begin":206,"end":212},"obj":"Disease"}],"attributes":[{"id":"A2","pred":"mondo_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/MONDO_0004992"}],"text":"monoclonal antibodies (mAbs) are approved or in late stage clinical trials, many of which harness the potent FcγR‐mediated effector systems to varying degrees. This is most evident for antibodies targeting cancer cells inducing antibo"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T9","span":{"begin":109,"end":111},"obj":"http://purl.obolibrary.org/obo/CLO_0052676"},{"id":"T10","span":{"begin":213,"end":218},"obj":"http://purl.obolibrary.org/obo/GO_0005623"}],"text":"monoclonal antibodies (mAbs) are approved or in late stage clinical trials, many of which harness the potent FcγR‐mediated effector systems to varying degrees. This is most evident for antibodies targeting cancer cells inducing antibo"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T4","span":{"begin":123,"end":131},"obj":"Chemical"}],"attributes":[{"id":"A4","pred":"chebi_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/CHEBI_35224"}],"text":"monoclonal antibodies (mAbs) are approved or in late stage clinical trials, many of which harness the potent FcγR‐mediated effector systems to varying degrees. This is most evident for antibodies targeting cancer cells inducing antibo"}

{"project":"LitCovid-sample-PD-IDO","denotations":[{"id":"T5","span":{"begin":213,"end":218},"obj":"http://purl.obolibrary.org/obo/CL_0000000"}],"text":"monoclonal antibodies (mAbs) are approved or in late stage clinical trials, many of which harness the potent FcγR‐mediated effector systems to varying degrees. This is most evident for antibodies targeting cancer cells inducing antibo"}

{"project":"LitCovid-sample-Pubtator","denotations":[{"id":"21","span":{"begin":109,"end":113},"obj":"Gene"},{"id":"26","span":{"begin":206,"end":212},"obj":"Disease"}],"attributes":[{"id":"A21","pred":"pubann:denotes","subj":"21","obj":"Gene:2213"},{"id":"A26","pred":"pubann:denotes","subj":"26","obj":"MESH:D009369"}],"text":"monoclonal antibodies (mAbs) are approved or in late stage clinical trials, many of which harness the potent FcγR‐mediated effector systems to varying degrees. This is most evident for antibodies targeting cancer cells inducing antibo"}

{"project":"LitCovid-sample-PD-FMA","denotations":[{"id":"T5","span":{"begin":213,"end":218},"obj":"Body_part"}],"attributes":[{"id":"A5","pred":"fma_id","subj":"T5","obj":"http://purl.org/sig/ont/fma/fma68646"}],"text":"monoclonal antibodies (mAbs) are approved or in late stage clinical trials, many of which harness the potent FcγR‐mediated effector systems to varying degrees. This is most evident for antibodies targeting cancer cells inducing antibo"}

{"project":"LitCovid-sample-PD-MONDO","denotations":[{"id":"T1","span":{"begin":206,"end":212},"obj":"Disease"}],"attributes":[{"id":"A1","pred":"mondo_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/MONDO_0004992"}],"text":"monoclonal antibodies (mAbs) are approved or in late stage clinical trials, many of which harness the potent FcγR‐mediated effector systems to varying degrees. This is most evident for antibodies targeting cancer cells inducing antibo"}

{"project":"LitCovid-sample-PD-HP","denotations":[{"id":"T1","span":{"begin":206,"end":212},"obj":"Phenotype"}],"attributes":[{"id":"A1","pred":"hp_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/HP_0002664"}],"text":"monoclonal antibodies (mAbs) are approved or in late stage clinical trials, many of which harness the potent FcγR‐mediated effector systems to varying degrees. This is most evident for antibodies targeting cancer cells inducing antibo"}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T1","span":{"begin":206,"end":212},"obj":"Phenotype"}],"attributes":[{"id":"A1","pred":"hp_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/HP_0002664"}],"text":"monoclonal antibodies (mAbs) are approved or in late stage clinical trials, many of which harness the potent FcγR‐mediated effector systems to varying degrees. This is most evident for antibodies targeting cancer cells inducing antibo"}